January 8, 2008. Sophia Antipolis, France - NicOx S.A. (Euronext Paris: COX) today announced it has signed an extension of its March 2006 collaboration agreement, which grants Pfizer Inc the exclusive right to apply its proprietary nitric oxide-donating technology to drug discovery researchin the field of ophthalmology.
This one-year extension of the research phase of the agreement will result in NicOx receiving €3 million in research funding in March 2008 and prolongs Pfizer’s option to license resulting compounds until May 2009... [PDF] NicOx' Press Release - PDF du Communiqué de Presse de NicOx-
